Quick Answer
Tempest Therapeutics, Inc. reported Earnings Per Share Diluted of $6.33 (loss) per share for the year ending 2025.
- Tempest Therapeutics, Inc. showed an increase of +67.5% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Tempest Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $10.55 (loss) per share | Q2 2021: $7.63 (loss) per share | Q3 2021: $1.21 (loss) per share | Q1 2022: $1.18 (loss) per share | Q2 2022: $0.79 (loss) per share | Q3 2022: $0.66 (loss) per share | Q1 2023: $0.55 (loss) per share | Q2 2023: $0.54 (loss) per share | Q3 2023: $0.48 (loss) per share | Q1 2024: $4.62 (loss) per share | Q2 2024: $5.52 (loss) per share | Q3 2024: $5.32 (loss) per share | Q1 2025: $3.16 (loss) per share | Q2 2025: $2.07 (loss) per share | Q3 2025: $0.79 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Tempest Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 84.6%.
- Historical annual values: Fiscal year 2025: $6.33 (loss) per share | Fiscal year 2024: $19.50 (loss) per share | Fiscal year 2023: $1.91 (loss) per share | Fiscal year 2022: $3.09 (loss) per share | Fiscal year 2021: $7.47 (loss) per share | Fiscal year 2020: $41.03 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: